Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
7.69
-0.16 (-2.04%)
At close: Jan 30, 2026, 4:00 PM EST
7.71
+0.02 (0.27%)
After-hours: Jan 30, 2026, 7:59 PM EST
Ardelyx Employees
Ardelyx had 395 employees as of December 31, 2024. The number of employees increased by 128 or 47.94% compared to the previous year.
Employees
395
Change (1Y)
128
Growth (1Y)
47.94%
Revenue / Employee
$1,008,187
Profits / Employee
-$143,157
Market Cap
1.87B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 395 | 128 | 47.94% |
| Dec 31, 2023 | 267 | 134 | 100.75% |
| Dec 31, 2022 | 133 | 47 | 54.65% |
| Dec 31, 2021 | 86 | -43 | -33.33% |
| Dec 31, 2020 | 129 | 41 | 46.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| MannKind | 407 |
| Vericel | 357 |
| Nuvation Bio | 291 |
| Ocular Therapeutix | 274 |
| Syndax Pharmaceuticals | 270 |
| Aurinia Pharmaceuticals | 130 |
| Stoke Therapeutics | 128 |
ARDX News
- 3 days ago - First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA - GlobeNewsWire
- 10 days ago - Ardelyx: Assessment Of Acquisition Rumors - Seeking Alpha
- 11 days ago - Ardelyx: IBSRELA Momentum Drives Opportunity - Seeking Alpha
- 23 days ago - Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook - GlobeNewsWire
- 3 months ago - Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week - GlobeNewsWire
- 3 months ago - Ardelyx to Participate at the Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 3 months ago - Ardelyx: Impressive Q3 Record Growth - Why I Buy - Seeking Alpha
- 3 months ago - Ardelyx: A Long Overdue Rally - Seeking Alpha